Terafan

Quick links to important sections

Terafan

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Terafan

Property Description
Active ingredient Terbinafine Hydrochloride
Forms Tablet (Oral), Cream, Solution, Spray (Topical)
Pharmacological class Allylamine Antifungal
General purpose Elimination of fungal infections
Origin Synthetic compound

What Type of Medicine is Terafan and What is it Made of?

Terafan is a medicinal preparation whose core component is the active substance Terbinafine Hydrochloride. It is definitively classified as an antifungal medicine and belongs to the allylamine pharmacological class. This classification is clinically recognized for its potent action against dermatophytes, which cause common skin and nail infections. The compound is synthetic, meaning it is chemically manufactured rather than directly extracted from natural sources. As a single-ingredient product, Terafan contains only Terbinafine Hydrochloride as its active constituent, combined with various pharmaceutical excipients appropriate for its final presentation. Its differentiation from older antifungals lies in its specific molecular target, resulting in a destructive effect on the fungal cell.

What is the General Purpose and Form of Terafan?

The general purpose of Terafan is to address and eliminate fungal infections by exerting a destructive, or fungicidal, effect on the responsible microorganisms. It is available in distinct forms to suit the location and depth of the infection. Terbinafine is supplied as oral tablets for systemic administration, which is typically required for treating stubborn nail infections, and as various topical preparations, such as creams, solutions, or sprays. The topical forms are designed for local application directly onto the skin surface for localized action, while the oral route ensures the medicine circulates throughout the body, targeting the fungal entity directly. This fungicidal property supports the drug's function as a foundational tool against mycotic conditions.

What side effects are possible with Terafan?

Possible Side Effects and Safety Information

General Adverse Reactions

The most commonly reported side effects (very common, affecting more than 1 in 10 people) include headache, gastrointestinal symptoms (such as diarrhea, indigestion, nausea, and abdominal pain), and musculoskeletal pain (joint or muscle pain). Other frequent side effects (common, affecting 1 to 10 in 100 people) are changes in taste or loss of taste, dizziness, and tiredness. Changes in taste can occasionally be severe or prolonged, leading to decreased appetite and weight loss.

Serious Safety Risks and Warnings

Official regulatory documents emphasize the potential for rare but serious adverse reactions, which include:

  • Hepatotoxicity (Liver Problems): Cases of severe liver failure, sometimes leading to liver transplant or death, have been reported. It is required to obtain liver enzyme tests before starting therapy. The drug is contraindicated in patients with pre-existing chronic or active liver disease.
  • Serious Skin Reactions: Very rare reports include life-threatening conditions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Any progressive or severe rash warrants immediate medical attention.
  • Blood Abnormalities: Very rarely, the medicine may affect blood cell counts, resulting in conditions like severe neutropenia (low white blood cells) or pancytopenia (low counts of all blood cell types).
  • Immunologic Conditions: Precipitation or exacerbation of conditions like systemic lupus erythematosus (SLE) and vasculitis have been reported.

Safety Considerations

Patients should be monitored for any signs of liver injury, such as persistent nausea, fatigue, right upper abdominal pain, dark urine, or yellowing of the skin or eyes. The drug can also affect the sense of smell and has been associated with the development of depressive symptoms. Patients who are breastfeeding should not use this medication as it is known to pass into breast milk.

Overdose and Emergency Response

Terafan Overdose and when to seek help

The following information details the officially documented signs and required emergency actions in case of Terbinafine (Terafan) overexposure, as reported in government regulatory documents.

Documented Overdose Manifestations
Gastrointestinal/Neurological Headache, Dizziness, Vomiting, Abdominal Pain, Epigastric Pain, Nausea
Other Signs Rash, Frequent Urination

When to Seek Immediate Medical Help

Immediate medical attention is mandated by regulatory bodies if an overdose occurs. Patients or caregivers must call emergency services or the Poison Help line immediately upon suspected overexposure. The regulatory profile is constrained by the risk of severe systemic toxicities, including liver failure and Thrombotic Microangiopathy (TMA).

Urgent evaluation is required if signs of liver injury develop, such as persistent nausea, unexplained vomiting, fatigue, dark urine, or jaundice. The drug must be discontinued immediately if clinical or biochemical evidence of liver damage is detected, or if serious events like severe skin reactions occur.

Officially Described Supportive Measures

Management is strictly symptomatic and supportive. No specific antidote is documented in regulatory labeling. To help eliminate the medicine following acute oral ingestion, regulatory guidance specifies the administration of activated charcoal.

Therapeutic Uses of Terafan

The primary therapeutic use of Terafan (Terbinafine) is for managing fungal infections, playing a role in managing the fungal organism to support mycological cure. Oral therapy may be considered relevant due to the site, severity, or extent of the infection, providing systemic action in contexts where topical treatments may not be effective.


The medication is commonly used across conditions presenting with deep-seated infections such as onychomycosis (fungal infections affecting the nails) and Tinea capitis (scalp ringworm), as well as extensive or persistent skin mycoses like athlete’s foot and jock itch. By addressing the manifestations of the condition, Terafan is relevant for managing symptom clusters related to intense itching, redness, scaling, and skin cracking. It assists in easing the overall symptom load and supports patients during episodes of heightened discomfort.

“This approach is relevant when systemic action may be appropriate to support the resolution of chronic or widespread symptoms.”

Quick Fact: Relief for Physical Discomfort Terafan provides supportive relief that helps ease the overall symptom burden, contributing to improved day-to-day comfort during periods marked by persistent scaling and persistent fungal activity.

Eligibility and Restrictions for Use

Terafan (Terbinafine) use is strictly governed by regulatory criteria defining eligible and restricted populations.

Contraindications and Absolute Restrictions

Use of Terafan is contraindicated in patients with a known history of hypersensitivity (allergic reaction) to terbinafine or any of the product's ingredients. The oral tablet form is also strictly contraindicated for individuals with chronic or active liver disease.

Use Restrictions for Specific Populations

Population Group Restriction (Oral Form) Restriction (Topical Form)
Renal Impairment Not recommended in severe impairment (CrCl < 50 mL/min) Not generally restricted
Pregnancy/Lactation Not recommended during pregnancy or while breastfeeding Not generally recommended
Pediatrics Established for children 4 years and older (for Tinea capitis) Not recommended under 12 years due to limited data

The oral medicine is officially not recommended for patients with severe kidney impairment. Similarly, use during pregnancy and breastfeeding is not recommended because of limited clinical experience or known excretion into milk. Age restrictions apply across formulations, with topical use typically reserved for those 12 years of age and older.

What should I know about interactions with other medicines?

The interaction profile for Terafan oral tablets is determined by its activity as a metabolic enzyme inhibitor. Terafan is officially documented as a potent inhibitor of the Cytochrome P450 CYP2D6 isozyme.

Drug–Drug Pharmacokinetic Interactions

Co-administration of Terafan with drugs metabolized by CYP2D6 can significantly increase their plasma concentrations. For example, the systemic exposure (AUC) of Desipramine, a tricyclic antidepressant, is officially increased approximately fivefold. This interaction is relevant for several classes of medicines, including certain SSRIs, beta-blockers, and Class 1C antiarrhythmics.

Other medicines alter the clearance of Terafan itself. Co-administration with the inducer Rifampicin results in a 100% increase in Terafan clearance, which significantly reduces its exposure. Conversely, inhibitors such as Fluconazole increase Terafan’s maximum plasma concentration ( C max) by 52% and AUC by 69%. Terafan also increases the clearance of Cyclosporine by 15%.

Pharmacodynamic Outcomes and Restrictions

Specific outcomes have been reported with co-administration: rare cases of changes in the International Normalized Ratio (INR) or prothrombin time have been observed with Warfarin. Menstrual disturbances have been reported with oral contraceptives.

Use of oral Terafan is contraindicated in patients with chronic or active hepatic disease. It is not recommended for patients with severe renal impairment (creatinine clearance lt 50 mL/min) due to inadequate study data regarding altered pharmacokinetics in this population. The absorption of Terafan tablets is not affected by food intake.

Mechanism of Action

The mechanism of action for Terafan exhibits high selectivity and initiates action within the domain of enzyme-mediated signaling, where it functions as a non-competitive inhibitor of the fungal enzyme squalene epoxidase. This enzyme controls a critical, early step in the ergosterol biosynthesis pathway.

The inhibition of squalene epoxidase triggers a dual mechanistic cascade. This molecular block simultaneously causes the depletion of the necessary cell membrane component, ergosterol, and leads to the buildup of the toxic substance squalene inside the fungal cell. The combination of structural failure and internal poisoning establishes the fungicidal (cell-killing) effect on the pathogen.

Terafan's chemical structure supports pathway interference by allowing it to accumulate readily in keratinous tissues like the skin and nails. This biological process ensures that the active substance achieves high, sustained local concentrations. This sustained exposure facilitates prolonged inhibitory pressure on the fungal enzyme, which is required for the action to be fully expressed.

Dosage and Administration Information

How Terafan is Used: Official Administration and Dosing

Terafan (Terbinafine) is used via two approved routes: oral (for systemic treatment of deeper infections like onychomycosis) and topical (for localized skin infections). The official instructions define the precise dosing, frequency, and duration for oral administration, ensuring consistent use.

Standard Adult Oral Dosing and Duration

The standard oral dosage for adults is a 250 mg tablet taken once daily. The duration of therapy is set by the location of the infection:

Condition Dose Frequency Duration of Therapy
Fingernail Onychomycosis 250 mg (Tablet) Once Daily 6 weeks
Toenail Onychomycosis 250 mg (Tablet) Once Daily 12 weeks

Administration Requirements and Specific Populations

Oral Terafan tablets may be taken with or without food. However, the oral granules—often used in children—must be mixed with a spoonful of soft, non-acidic food and swallowed without chewing.

For specific populations, use is constrained by pre-existing conditions. The oral medicine is not recommended for use in patients with significant renal impairment (Creatinine Clearance le 50 mL/min) or for those with chronic or active liver disease. Pediatric dosing is weight-based for tinea capitis, ranging from 125 mg to 250 mg daily, administered for a course of 6 weeks.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Terafan


Evidence for Onychomycosis (Fungal Nail Infection)

The research into oral Terafan for fungal nail infections, or onychomycosis, primarily relies on Randomized Controlled Trials (RCTs) and meta-analyses. These studies were designed to explore how this medicine compares to a dummy treatment (placebo) and to other antifungal medications taken by mouth. Researchers monitored two key outcomes: mycological clearance (lab tests confirming the fungus is gone) and clinical clearance (the visible growth of a clear, healthy nail).

Studies describe patterns observed in the measured outcomes, with measurements of mycological clearance being described in the studies. Because nails grow very slowly, patients were often followed for up to 12 months after they finished their treatment, which allows for the assessment of healthy nail growth. Findings reflect only the populations studied, meaning data for patients with certain specific, severe underlying health conditions remain insufficient.


Evidence for Tinea Capitis (Scalp Ringworm)

Terafan was studied for Tinea capitis, a fungal infection of the scalp, mostly affecting prepubertal children. The research consisted mainly of RCTs, where the medicine was compared against other established oral antifungal treatments. In these trials, the main focus was evaluated in relation to mycological clearance and the clinical observation of visible symptoms like scaling and hair loss.

Studies described patterns related to the different kinds of fungus that cause the infection. Specifically, findings were mixed when examining two different types of dermatophytes (Trichophyton vs. Microsporum), and the outcome patterns observed appears to vary depending on the specific fungal species involved. The evidence is limited regarding a universally optimal dosing period in children, particularly for infections caused by Microsporum.


Understanding the Evidence Gaps and Areas of Uncertainty

While the evidence contributes to the broader evidence landscape, there are notable research limitations. Evidence quality varies across studies, particularly older trials. Furthermore, a significant gap is that the long-term effects are not fully established across the evidence base, with limited information available on recurrence rates several years after treatment for both nail and skin infections. This means the research provides context regarding group patterns, but not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Terafan (FAQ)


Q: Is there a generic version of Terafan available?

Yes, the generic version of Terafan is widely available and is known as terbinafine hydrochloride. According to regulatory standards, generic versions must contain the same active ingredient and be bioequivalent to the brand-name product, meaning they are expected to work in the same way.


Q: Does Terafan cause weight gain?

Official information lists decreased appetite and weight loss as possible effects, which can sometimes occur due to changes in the sense of taste. However, weight gain is not explicitly listed as an adverse reaction in the official regulatory documents.


Q: Can Terafan affect sleep?

Regulatory documents indicate that sleep problems or insomnia have been reported as a possible side effect of Terafan. Patients who experience sleep disturbances should consult their healthcare provider.


Q: Can Terafan be taken with common pain relievers like ibuprofen?

Regulatory documents do not specifically list every non-prescription pain reliever like ibuprofen in the interaction profile. However, Terafan strongly affects the enzyme CYP2D6, which metabolizes many medications. Patients who use other medications should consult their healthcare provider for interaction guidance.


Q: Does Terafan interact with vitamins or supplements?

Official drug labels often state that there is not enough information to fully confirm that all complementary medicines, herbal remedies, and supplements are safe to take with prescription drugs. Patients are advised to inform their healthcare provider about all supplements they are taking.


Q: Is it okay to drink coffee while taking Terafan?

Official pharmacokinetic data indicates that Terafan can decrease the body's clearance of caffeine (found in coffee). This means the caffeine may stay in the body longer, potentially increasing caffeine-related side effects such as sleeplessness or nervousness.


Q: What happens if I miss a dose of Terafan?

Official instructions typically state that if a dose is missed, it should be taken as soon as possible, unless it is almost time for the next dose (e.g., less than four hours away). In that case, the dose is skipped, and the regular schedule is resumed. The guidance is not to take a double dose.


Q: How long does Terafan stay in your system after stopping it?

Studies on Terafan's movement in the body show an effective plasma half-life of approximately 36 hours. However, because the medicine accumulates readily in keratinous tissues like the nails and skin, small amounts can remain in the body tissues for up to three months after the final dose.


Q: Is Terafan suitable for older adults?

Regulatory reviews suggest there is no evidence that elderly patients (aged 65 years and above) require different dosages or experience different side effects compared to younger patients. However, before Terafan is prescribed, the patient’s pre-existing liver or kidney function is a factor that is typically assessed, as these conditions are more common in older adults.


Q: How often do I need follow-up appointments when taking Terafan?

While the specific schedule for clinical follow-up is determined by the healthcare provider, regulatory bodies require monitoring of liver enzyme tests before starting the medication. Regulatory warnings indicate that treatment may be discontinued if signs of liver injury develop.


Q: Is Terafan considered a controlled substance?

No, according to official drug scheduling by the DEA and other regulatory bodies, Terafan (terbinafine) is not classified as a controlled substance.


Q: Can I stop taking Terafan suddenly?

The official label advises that patients typically take the medication for the entire prescribed duration to minimize the chance of the infection returning. However, if symptoms of a serious side effect occur, such as a severe rash or signs of liver problems, the label advises immediate discontinuation and consultation with a healthcare professional.


Q: What should I do if I feel worse after starting Terafan?

The official medication guide indicates that patients should consult their healthcare provider immediately if they experience symptoms of a serious side effect. This includes signs of liver problems (such as persistent nausea, dark urine, or yellowing of skin or eyes) or the development of a progressive or severe rash.


Q: Is there a warning about using Terafan with alcohol?

While there is no direct alcohol interaction listed in the primary pharmacology section, regulatory bodies advise avoiding or limiting alcohol. This is because Terafan carries a risk of hepatotoxicity (liver problems), and due to the drug’s risk of causing liver damage, the use of alcohol is often advised against.


Q: What happens if I take a cold medicine while on Terafan?

Terafan inhibits the enzyme CYP2D6, which is involved in breaking down many common cold medicines. Taking them together could lead to increased levels of the cold medicine in the body, potentially increasing the risk of side effects. Patients are advised to inform their healthcare provider about all over-the-counter medicines they are taking.


Q: How long has Terafan been available?

Terafan (brand name Lamisil) was first approved for use in the United States by the FDA in 1996. This approval date serves as a point of reference for the drug’s regulatory history.


Q: Can people who are allergic to penicillin take Terafan?

The absolute contraindication for Terafan is a known history of allergy to the active ingredient, terbinafine, or any of the product's inactive ingredients. Official warnings do not specify that having a penicillin allergy alone restricts a person from taking Terafan.


Q: What is the difference between the brand name and generic versions of Terafan?

Regulatory agencies require the generic version, terbinafine hydrochloride, to be bioequivalent to the brand-name product. This means the generic contains the same active ingredient and is expected to work in the same way in the body, ensuring the same therapeutic effect.


Q: How quickly is Terafan supposed to start working?

Because the medicine works by stopping the fungus and allowing the healthy nail to grow, treatment is measured over the full duration of the prescribed course (typically 6 or 12 weeks). The full effect of a completely clear nail may take several months to become visible after the treatment course is finished.


Q: How long do common side effects from Terafan usually last?

Most common side effects often resolve within several weeks after stopping the treatment course. However, regulatory reports indicate that certain serious side effects, such as the loss or change of taste or smell, have occasionally been prolonged (lasting longer than one year) or, rarely, permanent.


Q: Does taking Terafan mean I have to change my diet?

Official regulatory prescribing information states that the oral tablets can be taken with or without food. There is no general requirement to change your diet while you are taking the tablets.


Q: Are there any food or drinks I should avoid while on Terafan?

It is generally advised to limit caffeine intake due to a potential interaction that can increase caffeine levels in your body. Also, due to the drug’s risk of causing liver damage, the use of alcohol is often advised against.


Q: What is the typical time frame for noticing a benefit from Terafan?

Clinical studies follow patients for up to 12 months because the drug must eliminate the fungus and wait for the new nail to fully grow out. Full visual improvement is typically measured in months. The visible benefit of a completely clear nail may take months to be observed after the course of treatment is finished.


Q: Does the official information recommend a specific time of day to take Terafan?

The medicine is prescribed to be taken once daily. While the exact time of day (morning or evening) is not specified in the official label, taking it at the same time every day is commonly recommended to help maintain a constant level of medicine in the body.


Q: What is the significance of the box warning (if any) on Terafan?

The official US label does not contain a Boxed Warning (often called a Black Box Warning). However, regulatory information contains serious warnings about the potential for rare but severe adverse events, including severe liver problems (hepatotoxicity) and serious skin reactions.


Q: Is the benefit of Terafan meant to be permanent or temporary?

The medicine is intended to achieve a cure of the fungal infection, known as mycological clearance. However, the label contains limited information on long-term outcomes, noting that recurrence rates several years after treatment are not fully established.


Q: How can I tell if Terafan is working for me?

Clinical studies measure success by mycological clearance and the visible growth of a clear, healthy nail. Patients may observe the growth of a new, clear nail starting at the base of the nail bed. This visual change is often consistent with the mycological clearance measured in clinical studies.


Q: Why do some people stop taking Terafan?

According to official warnings and adverse reaction reports, common reasons for discontinuation include the development of a progressive or severe rash, signs of liver injury (such as persistent nausea or jaundice), or severe taste disturbances.


Q: Are there any known issues with taking Terafan while driving?

The label lists dizziness and tiredness as common side effects of the medicine. Patients are advised to be aware of how they react to the medication before attempting to drive or operate machinery.


Q: Can I cut or crush the Terafan tablet?

The oral tablet is generally intended to be swallowed whole. If a patient has difficulty swallowing, while the regulatory text for the tablet does not specify cutting, any alteration to the tablet requires the guidance of a healthcare professional to confirm that the correct dose is maintained.

How should Terafan be stored and disposed of?

How to Store and Dispose of Terafan

Official labeling defines strict conditions to maintain Terafan's stability across all formulations.


Storage Requirements

Storage Element Requirement (Based on Regulatory Labeling)
Temperature Store at Controlled Room Temperature, between 20 C and 25 C (68 F to 77 F). Excursions up to 30 C are permitted.
Protection Keep the medicine in its original container and ensure the container is tightly closed. Topical forms must not be frozen.
Child Safety Keep this medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired Terafan must be handled carefully. Official instructions prohibit disposal via wastewater or household trash. Instead, the product must be discarded according to local requirements, which often involves returning it to a pharmacy or utilizing a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Terafan found in:

A-Z Index: